Drugs

, Volume 25, Issue 1, pp 6–40 | Cite as

Captopril: An Update Review of its Pharmacological Properties and Therapeutic Efficacy in Congestive Heart Failure

  • J. A. Romankiewicz
  • R. N. Brogden
  • R. C. Heel
  • T. M. Speight
  • G. S. Avery
Drug Evaluations

Summary

Synopsis: Captoprl1 is the first angiotensin-converting enzyme inhibitor for oral administration. In combination with continued digitalis and diuretic therapy it has been demonstrated to be effective in the management of severe heart failure refractory to optimal digitalis, diuretic and, in many patients, vasodilator treatment. Most studies to date have been open trials of several weeks or months duration, but a number of patients have received continued treatment, with sustained benefit, for up to 1 year or more. A placebo-controlled trial in a limited number of patients with less severe heart failure has confirmed the results of open trials. Captopril administration improves cardiac performance as a result of a reduction in systemic vascular resistance (afterload) and the various determinants of left ventricular filling pressure (preload). Improvements in exercise tolerance and functional classification, with associated reduction of clinical symptomatology, occur with simultaneous decreases in myocardial oxygen consumption.

At present, captopril is worthy of a trial in patients refractory to more traditional medical management. Whether it should be considered a ‘first-line’ agent after failure of optimal digitalis and diuretic therapy, and before instituting other vasodilator therapy, is less clear. In patients with severe or resistant heart failure, a response to captopril is usually accompanied by a general improvement in the quality of life. The effect of captopril treatment on 1- and 2-year survival rates in patients with severe heart failure appears similar to that reported for other vasodilators. Most patients tolerate captopril treatment well, but hypotension, reduced renal function, skin rash, dysgeusia, and neutropenia have been reported.

Pharmacodynamic Studies: Captopril is an orally effective inhibitor of angiotensin-converting enzyme, the enzyme responsible for conversion of inactive angiotensin I to angio tensin II. Angiotensin II is a potent vasoconstrictor and stimulator of aldosterone production and release. Captopril administration to normotensive and hypertensive animals and man, and to heart failure patients, reduces plasma angiotensin II and plasma and urinary aldosterone concentrations, and elevates plasma renin activity.

Part of captopril’s action may result from its influence on the kallikrein-kinin-prostaglandin system. However, data in this area have often been divergent, requiring additional study before definitive conclusions can be made. Although a reduction in urinary kallikrein activity follows captopril administration in animals and man, the clinical significance of this finding is not known. Some studies in man and animals reported increases in plasma and urinary bradykinin after captopril therapy, but other studies did not. No effect on plasma bradykinin was observed in 7 congestive heart failure patients treated with captopril. In vitro data suggest that captopril has a direct effect on prostacyclin production. In animal studies indomethacin has reduced captopril potentiation of bradykinin-induced bronchoconstriction and hypotension and prostaglandin release, but no antagonism of captopril’s effect on renal haemodynamics was observed. Either no change or increases in urinary prostaglandin E2 or F metabolites have followed captopril administration, and increases have correlated with the hypotensive response. The contribution of these effects to the action of captopril are not known.

In short term haemodynamic studies of captopril in patients with severe congestive heart failure, a number of beneficial effects have been observed. Administration of captopril (12.5 to 150mg) results in consistent increases in cardiac output (25 to 30%), cardiac index (15 to 40%) and stroke volume index (18 to 49%). The effects are accompanied by reductions in systemic vascular resistance (20 to 45%), pulmonary vascular resistance (35 to 45%), total vascular resistance (25 to 35%), pulmonary artery pressure (15 to 30%), pulmonary capillary wedge pressure (25 to 50%) and right atrial pressure (25 to 45%). A consistent fall in mean arterial pressure (7 to 25%) is generally seen but it rarely becomes symptomatic. After short term administration a slight reduction in heart rate occurs which generally returns to pre-captopril levels with long term therapy. Occasionally, a more marked reduction in heart rate may occur.

In studies involving a small number of patients with heart failure, a reduction in coronary blood flow (14%), which correlated with a fall in myocardial oxygen demand, has been observed with simultaneous increases in cardiac index and reduction in systemic vascular resistance. Preliminary data comparing captopril with hydralazine and prazosin suggest that captopril improves cardiac performance as do the other agents, but captopril has a greater effect on lowering myocardial oxygen demand.

In limited studies involving heart failure patients, divergent findings regarding the short term effect of captopril on renal blood flow, filtration fraction and glomerular filtration have been reported. Most short term studies report an increase in renal blood flow and a reduction in filtration fraction with no consistent effect on glomerular filtration rate. Transient deterioration in these parameters has also been observed, which correlates with the short term blood pressure-lowering effect. With continued therapy, these parameters return to pre-captopril levels as a result of reduced renal vascular resistance. However, long term captopril therapy has usually resulted in improved renal function in severely ill patients with heart failure. Additionally, pre-existing hyponatraemia and hypokalaemia have been normalised during long term captopril administration.

Pharmacokinetic Studies: In healthy fasting patients, 70% of an orally administered dose of captopril is absorbed. In heart failure patients a single dose of 25mg produced peak blood concentrations of about 120 ng/ml 1.4 hours after administration. Captopril is about 30% protein bound. In rats it does not enter the central nervous system, and in humans does not readily enter breast milk. Approximately 35% of a dose undergoes renal elimination as unchanged drug. Renal elimination correlates with creatinine clearance, requiring dosage adjustment in more severe stages of renal dysfunction.

Therapeutic Trials: Studies to date have primarily involved patients with severe, often resistant, heart failure. All patients received continued therapy with digitalis and diuretics during captopril administration. Many open trials involving small numbers of these patients (New York Heart Association Functional Class III or IV) have clearly demonstrated the effectiveness of captopril. Captopril administration (37.5mg to 450mg daily) for several weeks or months, or in a number of patients for 1 year or more, has resulted in sustained improvement in cardiac haemodynamics, similar to those observed after short term administration. Improved ejection fraction (22 to 120%), reductions in left ventricular diastolic dimension (7%), and increased exercise tolerance time (33 to 83%) accompanied a reduction in cardiac oxygen utilisation, and improvement in New York Heart Association Functional Class has reflected improvement in cardiac haemodynamics. These beneficial effects have been confirmed in a double-blind placebo-controlled evaluation in patients with somewhat less severe heart failure.

Side Effects: The most frequently observed side effect associated with captopril administration to heart failure patients is hypotension. Approximately 50% of patients experience an acute fall in mean arterial pressure of 20%, which is rarely symptomatic and with continued therapy usually returns to levels not significantly different from baseline values. When symptoms have occurred, they usually subsided despite continued therapy, or with a dosage reduction of either captopril or the concomitantly administered diuretic. Skin rash (7% of patients) and taste alterations (3%) have also been reported in heart failure patients. (Interestingly, their incidence is approximately 50% of that seen in the hypertensive population.) Both of these side effects are reversible with discontinuation of therapy, or in some cases with continued therapy at the same or lower doses.

The most frequent haematological reaction associated with captopril is neutropenia. Most recent evidence suggests that in patients with normal renal function the incidence of neutropenia associated with captopril is low (0.02%), but the incidence is higher in patients with renal dysfunction (0.4%), and much higher in patients with elevated serum creatinine as well as collagen-vascular diseases such as lupus or scleroderma (7.2%). Transient deterioration in renal function tests has been associated with the initial fall in mean arterial pressure. About 20% of heart failure patients experience modest deterioration in renal function tests usually with stabilisation at a new level. Occasionally, severe deterioration has occurred which responded to discontinuation of therapy. However, in a limited number of long term treated severe heart failure patients with pre-existing renal disease, improvement in indexes of renal function has resulted. Although proteinuria (1.1%) and a few cases of nephrotic syndrome have occurred in hypertensive patients on long term treatment with captopril, similar findings have not been observed to date in the heart failure population with the exception of a single patient who developed the nephrotic syndrome, reflecting either the limited long term treatment experience in this population, a different effect of the diseases on the kidney or the generally lower doses of captopril used in patients with heart failure.

Dosage and Administration: The usual initial dosage of captopril for the management of the heart failure patient refractory to optimal therapy with digitalis and diuretics and/ or vasodilators is 25mg 3 times daily. Initial doses lower than 25mg may minimise any hypotensive effect and in some patients may be therapeutically adequate. Patients have responded to doses as low as 6.25mg. Subsequent dosage should be titrated and individualised according to clinical response, with most patients requiring 25 to 50mg 3 times daily. Wherever possible, increases in dosage beyond 50mg 3 times daily should be instituted only after a minimum interval of 2 weeks to allow adequate time for the maximum response at the previous dosage level to occur. The maximum recommended dose is 450mg daily. Careful blood pressure monitoring during dosage titration is essential because of potentially abrupt blood pressure falls. Particular caution in this regard is necessary in sodium- or volume-depleted patients. Optimum digitalis and diuretic therapy should be continued during captopril administration. Since potassium retention may accompany captopril therapy, potassium-sparing diuretics and potassium supplements should be used with caution. Routine periodic assessment of urinary protein should be performed in patients with a history of renal disease, or who are receiving high doses of captopril. Periodic evaluation of haematological status, especially white cell count, is necessary for ‘high risk’ patients; i.e., those with renal impairment, connective tissue disease and/or patients receiving other drugs known to affect the white blood cells or immune response. Dosage should be adjusted according to creatinine clearance in patients with severe renal disease, using the established guidelines.

Keywords

Heart Failure Captopril Heart Failure Patient Prazosin Renal Blood Flow 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Aberg, H.; Morlin, C. and Frithz, G.: Captopril-associated lymphadenopathy. British Medical Journal 283: 1297–1298 (1981).PubMedCrossRefGoogle Scholar
  2. Ader, R.; Chatterjee, K.; Ports, T.; Brundage, B.; Hiramatsu, B. and Parmley, W.: Immediate and sustained hemodynamic and clinical improvement in chronic heart failure by an oral angiotensin-converting enzyme inhibitor. Circulation 61: 931–937 (1980).PubMedCrossRefGoogle Scholar
  3. Amann, F.W.; Buhler, F.M.R.; Coneu, D.; Brunner, F.N.; Ritz, R. and Speck, B.: Captopril-associated agranulocytosis. Lancet 1: 50 (1980).Google Scholar
  4. Anderson, G.H.; Springer, J.; Tivnar, E.; Kearney, M. and Steeten, D.H.P.: Hypotensive mechanism of captopril. Clinical Research 28: 328 (1980).Google Scholar
  5. Antonaccio, M.J.; Harris, D.; Goldenberg, H.; High, J.P. and Rubin, B.: The effects of captopril, propranolol and indomethacin on blood pressure and plasma renin activity in spontaneously hypertensive and normotensive rats (40697). Proceedings of the Society for Experimental Biology and Medicine 162: 429–433 (1979).PubMedGoogle Scholar
  6. Atkinson, A.B.; Brown, J.J.; Lever, A.F.; McAreavey, D.; Robertson, J.I.S.; Behan, P.O.; Melville, I.D. and Weir, A.I.: Neurological dysfunction in two patients receiving captopril and cimetidine. Lancet 2: 36–37 (1980).PubMedCrossRefGoogle Scholar
  7. Awan, N.A.; Hermanovich, J.; Skinner, P. and Mason, D.T.: Captopril compared to prazosin in heart failure: equal preload reduction with dissimilar pump output effects. Circulation 59/60 (Suppl. 2): 180 (1979).Google Scholar
  8. Awan, N.A.; Evenson, M.K.; Needham, K.E.; Wing, A. and Mason, D.T.: Efficacy of oral angiotensin-converting enzyme inhibition with captopril therapy in severe chronic normotensive congestive heart failure. American Heart Journal 101: 22–31 (1981).PubMedCrossRefGoogle Scholar
  9. Awan, N.A.; Amsterdam, E.A.; Hermanovich, J.; Bommer, W.J.; Needham, K.E. and Mason, D.T.: Long term hemodynamic and clinical efficacy of captopril therapy in ambulatory management of severe chronic congestive heart failure. American Heart Journal 103: 474–479 (1982).PubMedCrossRefGoogle Scholar
  10. Banks, R.A. and Beilin, L.J.: The effects of meclofenamate, captopril and phentolamine on organ blood flow in the conscious rabbit. Clinical Science 61: 97–105 (1981).PubMedGoogle Scholar
  11. Bass, T.A.; Faxon, D.P.; Halperin, J.L.; Creager, M.A.; Melidossian, C.D.; Gavras, H. and Ryan, T.J.: Coronary hemodynamic effects of angiotensin inhibition in congestive heart failure. Clinical Research 29: 176A (1981).Google Scholar
  12. Brivet, F.; Delfraissy, J.-F.; Giudicelli, J.-F.; Richer, C.; Legrand, A. and Dormont, J.: Immediate effects of captopril in acute left ventricular failure secondary to myocardial infarction. European Journal of Clinical Investigation 11: 369–373 (1981).PubMedCrossRefGoogle Scholar
  13. Brown, J.J.; Davies, D.L.; Johnston, V.W.; Lever, A.F. and Robertson, J.I.S.: Renin relationships in congestive heart failure, treated and untreated. American Heart Journal 80: 329–342 (1970).PubMedCrossRefGoogle Scholar
  14. Captopril Collaborative Study Group: Does captopril cause renal damage in hypertensive patients? Report from the captopril collaborative study group. Lancet 1: 988–990 (1982).Google Scholar
  15. Case, D.B.; Atlas, S.A.; Mouradian, J.A.; Fishman, R.A.; Sherman, R.L. and Laragh, J.H.: Proteinuria during long-term captopril therapy. Journal of the American Medical Association 244: 346–349 (1980).PubMedCrossRefGoogle Scholar
  16. Case, D.B.; Whitman, H.H.; Laragh, J.H. and Spiera, H.: Successful low dose captopril rechallenge following drug-induced leucopenia. Lancet 1: 1362–1363 (1981).CrossRefGoogle Scholar
  17. Chatterjee, K. and Rouleau, J.-L.: Hemodynamic and metabolic effects of vasodilators, nitrates, hydralazine, prazosin and captopril in chronic ischemic heart failure. Acta Medica Scandinavica 651 (Suppl.): 295–303 (1981).PubMedGoogle Scholar
  18. Chatterjee, K.; Rouleau, J.L. and Parmley, W.W.: Haemodynamic and myocardial metabolic effects on captopril in chronic heart failure. British Heart Journal 47: 233–238 (1982).PubMedCrossRefGoogle Scholar
  19. Cody, R.J.; Franklin, K.W.; Kluger, J. and Laragh, J.H.: Sympathetic responsiveness and plasma norepinephrine during therapy of chronic congestive heart failure with captopril. American Journal of Medicine 72: 791–797 (1982a).PubMedCrossRefGoogle Scholar
  20. Cody, R.J.; Kluger, J.; Sealey, J.E. and Laragh, J.H.: The reninangiotensin system in chronic congestive heart failure. American Journal of Cardiology 49: 1036 (1982b).CrossRefGoogle Scholar
  21. Cody, R.J.; Franklin, K.W. and Laragh, J.H.: Postural hypotension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. American Heart Journal 103: 480–484 (1982c).PubMedCrossRefGoogle Scholar
  22. Cody, R.J.; Covit, A.; Shaer, G. and Williams, G.: Captopril pharmacokinetics in chronic heart failure: Correlation with acute hemodynamic and hormonal response. American Journal of Cardiology 49: 925 (1982d).CrossRefGoogle Scholar
  23. Cohn, J.N.: Systemic vascular resistance: Regulation and effect on left ventricular function; in Case, Sonnenblick and Laragh (Eds) Captopril and Hypertension, pp.77–86 (Plenum Medical Book Company, New York 1980).CrossRefGoogle Scholar
  24. Cohn, J.N.; Levine, T.B.; Francis, G.S. and Goldsmith, S.: Neurohumoral control mechanisms in congestive heart failure. American Heart Journal 102: 509–514 (1981).PubMedCrossRefGoogle Scholar
  25. Cohn, J.N. and Levine, T.B.: Angiotensin-converting enzyme inhibition in congestive heart failure: The concept. American Journal of Cardiology 49: 1480–1483 (1982).PubMedCrossRefGoogle Scholar
  26. Cooper, R.A.: Captopril-associated neutropenia: Who is at risk? Archives of Internal Medicine (In press, 1982).Google Scholar
  27. Creager, M.A.; Halperin, J.L.; Bernard, D.B.; Faxon, D.P.; Melidossian, C.D.; Gavras, H. and Ryan, T.J.: Acute regional circulatory and renal hemodynamic effects of converting-enzyme inhibition in patients with congestive heart failure. Circulation 64: 483–489 (1981).PubMedCrossRefGoogle Scholar
  28. Curtiss, C.; Cohn, J.N.; Urobel, T. and Franciosa, J.A.: Role of the renin angiotensin system in the systemic vasoconstriction of chronic congestive heart failure. Circulation 58: 763–770 (1979).CrossRefGoogle Scholar
  29. Davidson, D.; Stalcup, S.A. and Mellins, R.B.: Captopril administration to the pregnant guinea pig inhibits fetal angiotensin converting enzyme activity. Pediatric Research 15: 658 (1981).CrossRefGoogle Scholar
  30. Davis, R.; Ribner, H.S.; Keung, E.; Sonnenblick, E.H. and Le-Jemtel, T.H.: Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. New England Journal of Medicine 301: 117–121 (1979).PubMedCrossRefGoogle Scholar
  31. Devlin, R.G. and Fleiss, P.M.: Captopril in human blood and breast milk. Journal of Clinical Pharmacology 21: 110–113 (1981).PubMedGoogle Scholar
  32. Duchin, K.L.; Singhvi, S.M.; Willard, D.A.; Migdalof, B.H. and McKinstry, D.N.: Captopril kinetics. Clinical Pharmacology and Therapeutics 31: 452–458 (1982).PubMedCrossRefGoogle Scholar
  33. Dzau, V.J.; Colucci, W.S.; Williams, G.H.; Curfman, G.; Meggs, L. and Hollenberg, N.K.: Sustained effectiveness of converting-enzyme inhibition in patients with severe congestive heart failure. New England Journal of Medicine 302: 1373–1379 (1980).PubMedCrossRefGoogle Scholar
  34. Dzau, V.J.; Colucci, W.S.; Hollenberg, N.K. and Williams, G.H.: Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 63: 645–651 (1981).PubMedCrossRefGoogle Scholar
  35. Faxon, D.P.; Halperin, J.L.; Creager, M.A.; Gavras, H.; Schick, E.C. and Ryan, T.J.: Angiotensin inhibition in severe heart failure: acute central and limb hemodynamic effects of captopril with observations on sustained oral therapy. American Heart Journal 101: 548–556 (1981).PubMedCrossRefGoogle Scholar
  36. Fitzgerald, D.J.; O’Callaghan, W.G.; O’Brien, E.T.; O’Malley, K. and Horgan, J.: Comparison of captopril and hydralazine in refractory heart failure: An acute haemodynamic study. Irish Journal of Medical Science 51: 30 (1982a).Google Scholar
  37. Fitzgerald, D.J.; O’Callaghan, W.G.; O’Brien, E.T. and O’Malley, K.: Acute haemodynamic and long term responses to hydralazine and captopril in congestive heart failure. The importance of preload reduction. Presented at Captopril Update Symposium, Salzburg, Austria, June 17–18 (1982b).Google Scholar
  38. Fouad, F.M.; Tarazi, R.C. and Bravo, E.L.: Successful management of heart failure (HF) with captopril. Relation to angiotensin II-aldosterone suppression. World Conference on Clinical Pharmacology and Therapeutics, London, August 3–9 (1980).Google Scholar
  39. Fouad, M.F.; Tarazi, R.C.; Bravo, E.L.; Hart, N.J.; Castle, L.W. and Salcedo, E.E.: Long-term control of congestive heart failure with captopril. American Journal of Cardiology 49: 1489–1496(1982).PubMedCrossRefGoogle Scholar
  40. Froer, K.L.; Hall, D.; Blasini, R. and Rudolph, W.: Prazosin versus captopril in patients with congestive heart failure. American Journal of Cardiology 49: 988 (1982).CrossRefGoogle Scholar
  41. Gavras, H.; Faxon, D.P.; Berkoben, J.; Brunner, H.R; and Ryan, T.J.: Angiotensin converting enzyme inhibition in patients with congestive heart failure. Circulation 58: 770–776 (1979).CrossRefGoogle Scholar
  42. Gavras, I.; Graff, L.G.; Rose, B.D.; McKenna, J.M.; Brunner, H.R. and Gavras, H.: Fatal pancytopenia associated with the use of captopril. Annals of Internal Medicine 94: 58–59 (1981).PubMedGoogle Scholar
  43. Goldsmith, S.R.; Francis, G.S.; Levine, T.B.; Cowley, A. and Cohn, J.N.: Elevated arginine vasopressin levels in congestive heart failure and response to nitroprusside and captopril. Clinical Research 29: 495A (1981).Google Scholar
  44. Greenberg, R.; Osman, G.H.; O’Keefe, E.H. and Antonaccio, M.J.: The effects of captopril (SQ 14,225) on bradykinin-induced bronchoconstriction in the anesthetized guinea pig. European Journal of Pharmacology 57: 287–294 (1979).PubMedCrossRefGoogle Scholar
  45. Heald, A.F. and Ita, C.E.: Distribution in rats of an inhibitor of angiotensin-converting enzyme, SQ 14,225, as studied by whole-body autoradiography and liquid scintillation counting. Pharmacologist 19: 129 (1977).Google Scholar
  46. Heel, R.C.; Brogden, R.N.; Speight, T.M. and Avery, G.S.: Captopril: A preliminary review of its pharmacological properties and therapeutic efficacy. Drugs 20: 409–452 (1980).PubMedCrossRefGoogle Scholar
  47. Hirakata, H.; Onoyama, K.; Iseki, K.; Omae, T.; Sujimi, S. and Kawahara, Y.: Captopril (SQ 14,225) clearance during hemodialysis treatment. Clinical Nephrology 16: 321–323 (1981).PubMedGoogle Scholar
  48. Hollenherg, N.K. and Williams, G.H.: The renin-angiotensin system in congestive heart failure. Journal of Cardiovascular Medicine 6: 359–369 (1981).Google Scholar
  49. Hoorntje, S.J.; Donker, A.J.M.; Prins, E.J.L. and Weening, J.J.: Membranous glomerulopathy in a patient on captopril. Acta Medica Scandinavica 208: 325–329 (1980).PubMedCrossRefGoogle Scholar
  50. Ikram, H.; Maslowski, A.H. and Nicholls, M.G.: Haemodynamic effects of dobutamine in patients with congestive heart failure receiving captopril. British Heart Journal 45: 528–530 (1981).CrossRefGoogle Scholar
  51. Ita, C.E.; Singhvu, S.M.; Heald, H.F. and Migdalof, B.H.: Distribution of captopril to fetuses and milk of rats. Xenobiotica (In press, 1982).Google Scholar
  52. Johnston, C.I.; McGrath, B.P.; Millar, J.A. and Matthews, P.G.: Long term effects of captopril on blood pressure and hormone levels in essential hypertension. Lancet 2: 493–495 (1979a).PubMedCrossRefGoogle Scholar
  53. Johnston, C.I.; McGrath, B.P. and Matthews, P.G.: Comparison of the hormonal effects of captopril (SQ 14,225) and hydrochlorothiazide in the treatment of essential hypertension. Medical Journal of Australia 2(Suppl): 17–22 (1979b).Google Scholar
  54. Kallenberg, C.G.M.; Hoorntje, S.J.; Smit, A.J.; Weening, J.J.; Donker, A.J.M. and Hoedemaeker, T.H.: Antinuclear and antinative DNA antibodies during captopril treatment. Acta Medica Scandinavica 211: 297–300 (1982).PubMedCrossRefGoogle Scholar
  55. Kayanakis, J.G.; Giraud, P.; Fauvel, J.M. and Bounhoure, J.P.: Eosinophilia during captopril treatment. Lancet 2: 923 (1980).PubMedCrossRefGoogle Scholar
  56. Kayanakis, J.G.; Fauvel, J.M.; Giraud, P. and Bounhoure, J.P.: Long-term treatment of congestive heart failure by captopril: hemodynamic, biological and clinical effects. European Heart Journal 2: 75–81 (1981).PubMedGoogle Scholar
  57. Keim, G.R.; Sibley, P.L.; Zaidi, I.H.; Keysser, C.H.; Kulesza, J.S.; Yoon, Y.H. and Zaki, F.G.: Effects of chronic inhibition of angiotensin-converting enzyme by captopril in normotensive animals. Society of Toxicology Annual Conference, Washington, D.C., March 13 (1980).Google Scholar
  58. Keishi, A.: Captopril-induced PG release may contribute to its antihypertensive mechanism. Acta Therapeutica 6 (Suppl.): 14 (1980).Google Scholar
  59. Kincaid-Smith, P.; Whitworth, J.A.; Walter, N.M.A. and Dowling, J.P.: Immune complex glomerulopathy and captopril. Lancet 2: 37 (1980).PubMedCrossRefGoogle Scholar
  60. Kluger, J.; Cody, R.J. and Laragh, J.H.: The contributions of sympathetic tone and the renin angiotensin system to severe chronic congestive heart failure: Response to specific Inhibitors (prazosin and captopril). American Journal of Cardiology 49: 1667–1674 (1982).PubMedCrossRefGoogle Scholar
  61. Komai, T.; Ikeda, T.; Kawai, K.; Kameyama, E. and Shindo, H.: In vitro studies on the metabolic pathway of SQ 14,225 (captopril) and mechanism of mixed disulfide formation. Journal of Pharmacobiodynamics 4: 677–684 (1981).CrossRefGoogle Scholar
  62. Kramer, B.; Massie, B. and Topie, N.: Controlled trial of captopril for heart failure: Effects on hemodynamics, scintigraphy and exercise tolerance. American Journal of Cardiology 49: 925 (1982).CrossRefGoogle Scholar
  63. Kripalani, K.J.; McKinstry, D.N.; Singhvi, S.M.; Willard, D.A.; Vokovich, R.A. and Migdalof, B.M.: Disposition of captopril in normal subjects. Clinical Pharmacology and Therapeutics 27: 636–641 (1980a).PubMedCrossRefGoogle Scholar
  64. Kripalani, K.J.; Meeker, F.S.; Dean, A.V.; McKinstry, D.N. and Migdalof, B.H.: Biotransformation of l4C-captopril in hypertensive patients and normal subjects. Federation Proceedings 39: 307 (1980b).Google Scholar
  65. Kubo, S.; Nichioka, A.; Nichimura, H.; Sonotani, N. and Takatsu, T.: The renin-angiotensin-aldosterone system and catecholamines in chronic congestive heart failure. Effect of angiotensin-I converting enzyme inhibitor SQ-14225 (captopril). Japanese Circulation Journal 44: 427–437 (1980).PubMedCrossRefGoogle Scholar
  66. LaBarre, T.R.; O’Connell, J.B. and Gunnar, R.M.: Captopril therapy for severe CHF: Hypotensive response in presence of markedly elevated PRA. American Heart Journal 103: 308–310 (1982).PubMedCrossRefGoogle Scholar
  67. Lee, C.L. and Walsh, W.F.: Comparison of captopril and prazosin in patients with refractory heart failure. Australian and New Zealand Journal of Medicine 12: 323 (1982).CrossRefGoogle Scholar
  68. Levine, T.B.; Franciosa, J.A. and Cohn, J.N.: Acute and long-term response to an oral converting-enzyme inhibitor, captopril, in congestive heart failure. Circulation 62: 35–41 (1980).PubMedCrossRefGoogle Scholar
  69. Levine, T.B.; Francis, G.S.; Goldsmith, S.R.; Simon, A.B. and Cohn, J.N.: Activity of the sympathetic nervous system and renin angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. American Journal of Cardiology 49: 1659–1666 (1982).PubMedCrossRefGoogle Scholar
  70. Liebau, G.; Riegger, A.J.G. and Steilner, H.: Haemodynamic effects of captopril in patients with congestive heart failure and hypertension; in Brunner and Gross (Eds) Recent Advances in Hypertension Therapy. Captopril, pp.76–87 (Excerpta Medica, Amsterdam 1980).Google Scholar
  71. Luderer, J.R.; Schneck, D.W.; Demers, L.M.; McKinstry, D.N.; Vary, J.E. and Hayes, A.H.: The humoral effects of captopril and furosemide in hypertensive patients. Clinical Pharmacology and Therapeutics 27: 268 (1980).Google Scholar
  72. Luderer, J.R.; Schoolwerth, A.C.; Sinicrope, R.A.; Ballard, J.O.; Lookingbill, D.P. and Hayes, A.H.: Acute renal failure, hemolytic anemia and skin rash associated with captopril therapy. American Journal of Medicine 71: 493–496 (1981).PubMedCrossRefGoogle Scholar
  73. Luderer, J.R.; Lookingbill, D.P.; Schneck, D.W.; Demers, L.M.; Cohen, C. and Hayes, A.H.: Captopril induced skin eruptions. Journal of Clinical Pharmacology 22: 151–159 (1982).PubMedGoogle Scholar
  74. Maeda, T.; Tanaka, K.; Kawameta, W.; Komai, T. and Shindo, H.: Studies on the metabolism of a new antihypertensive agent, SQ 14,225 (captopril). I. In vitro studies on the binding to plasma protein and behaviour in blood. 99th Annual Meeting Pharmaceutical Society of Japan, Sapporo, August 28–30 (1979).Google Scholar
  75. Marson, O.; Ribeiro, A.B.; Tufik, S.; Kohlmann Jr, O. and Ramos, O.L.: Inhibition of central angiotensin-I conversion by oral captopril. Brazilian Journal of Medical and Biological Research 14: 73–76 (1981).PubMedGoogle Scholar
  76. Maslowski, A.H.; Ikram, H.; Nicholls, M.G. and Espiner, E.A.: Haemodynamic, hormonal and electrolyte responses to captopril in resistant heart failure. Lancet 1: 71–73 (1981a).PubMedCrossRefGoogle Scholar
  77. Maslowski, A.H.; Nicholls, M.G.; Ikram, H.; Espiner, E.A. and Turner, J.G.: Haemodynamic, hormonal and electrolyte responses to withdrawal of long-term captopril treatment for heart failure. Lancet 2: 959–961 (1981b).PubMedCrossRefGoogle Scholar
  78. Massie, B.; Ponts, T.; Chatterjee, K.; Parmley, W.; Ostland, J.; O’Young, J. and Haughom, F.: Long term vasodilator therapy for heart failure: Clinical response and its relationship to hemodynamic measurements. Circulation 63: 269–278 (1981).PubMedCrossRefGoogle Scholar
  79. Massie, B.; Kramer, B.L.; Topic, N. and Henderson, S.G.: Hemodynamic and radionuclide effects of acute captopril therapy for heart failure: Changes in left and right ventricular volumes and function at rest and during exercise. Circulation 65: 1374–1381 (1982).PubMedCrossRefGoogle Scholar
  80. McGrath, B.P.; Denham, I.M. and Johnston, C.I.: Clinical improvement and hormonal changes in severe cardiac failure after captopril treatment. Australian and New Zealand Journal of Medicine 11: 639–644 (1981).PubMedCrossRefGoogle Scholar
  81. McKinstry, D.N.; Singhvi, S.M.; Kripalani, K.J.; Dreyfuss, J.; Willard, D.A. and Vukovich, R.A.: Disposition and cardiovascular-endocrine effects of an orally active angiotensin-converting enzyme inhibitor, SQ 14,225, in normal subjects. Clinical Pharmacology and Therapeutics 23: 121–122 (1978).Google Scholar
  82. McNeil, J.J.; Anderson, A.; Christophidis, N.; Jarrott, B. and Louis, W.J.: Taste loss associated with oral captopril treatment. British Medical Journal 2: 1555–1556 (1979).PubMedCrossRefGoogle Scholar
  83. Millar, J.F. and Johnston, C.L.: Sequential changes in circulating levels of angiotensin I and II, renin and bradykinin after captopril. Medical Journal of Australia 2 (Suppl.): 15–17 (1979).Google Scholar
  84. Montgomery, A.J.; Shepherd, A.N. and Emslie-Smith, D.: Severe hyponatremia and cardiac failure successfully treated with captopril. British Medical Journal 284: 1085–1086 (1982).PubMedCrossRefGoogle Scholar
  85. Mujais, S.K.; Fouad, F.M.; Textor, S.C.; Tarazi, R.C. and Bravo, E.L.: Contrast between acute and chronic effects of converting enzyme inhibition on renal function in heart failure. Clinical Research 29: 472A (1981a).Google Scholar
  86. Mujais, S.K.; Fouad, F.M.; Textor, S.C.; Tarazi, R.C. and Bravo, E.L.: Contrasting acute and chronic renal hemodynamic effects of captopril in congestive heart failure. Clinical Research 29: 752A (1981b).Google Scholar
  87. Murthy, V.S.; Waldron, T.L. and Goldberg, M.E.: The mechanism of bradykinin potentiation after inhibition of angiotensinconverting enzyme by SQ 14,225 in conscious rabbits. Circulation Research 43 (Suppl. 1): 40–45 (1978).Google Scholar
  88. Nicholls, M.G.; Espiner, E.A.; Donald, R.A. and Hughes, H.: Aldosterone and its regulation during diuresis in patients with gross congestive heart failure. Clinical Science and Molecular Medicine 47: 301–315(1974).PubMedGoogle Scholar
  89. Nicholls, M.G.; Espiner, E.A.; Ikram, H. and Maslowski, A.H.: Hyponatremia in congestive heart failure during treatment with captopril. British Medical Journal 281: 909 (1980).PubMedCrossRefGoogle Scholar
  90. Nicholls, M.G.; Espiner, E.A.; Ikram, H. and Maslowski, A.H.: Hemodynamic and hormonal responses to captopril withdrawal in heart failure. Clinical Research 29: 227A (1981a).Google Scholar
  91. Nicholls, M.G.; Maslowski, A.H.; Ikram, H. and Espiner, E.A.: Ulceration of the tongue: a complication of captopril therapy. Annals of Internal Medicine 94: 659 (1981b).PubMedGoogle Scholar
  92. Nicholls, M.G.; Espiner, E.A.; Ikram, H.; Maslowski, A.H.; Lun, S. and Scandrett, M.S.: Angiotensin II is more potent than potassium in regulating aldosterone in cardiac failure: evidence during captopril therapy. Journal of Clinical Endocrinology and Metabolism 52: 1253–1256 (1981c).PubMedCrossRefGoogle Scholar
  93. Nishith, S.; Davis. L.; and Youmans, W.: Cardioaccelerator action of angiotensin. American Journal of Physiology 202: 237–240 (1962).PubMedGoogle Scholar
  94. Oktay, S.; Onur, R.; Ilhan, M. and Turker, R.K.: Potentiation of the morphine-induced respiratory rate depression by captopril. European Journal of Pharmacology 70: 257–262 (1981).PubMedCrossRefGoogle Scholar
  95. Onoyama, K.; Hirakata, H.; Iseki, K.; Fujimi, S.; Omae, T.; Kobayashi, M. and Kawahara, Y.: Blood concentration and urinary excretion of captopril (SW 14,225) in patients with chronic renal failure. Hypertension 3: 456–459 (1981).PubMedCrossRefGoogle Scholar
  96. Oparil, S. and Haber, E.: I. The renin-angiotensin system. New England Journal of Medicine 291: 389–401 (1974a).PubMedCrossRefGoogle Scholar
  97. Oparil, S. and Haber, E.: II. The renin-angiotensin system. New England Journal of Medicine 291: 446–457 (1974b).PubMedCrossRefGoogle Scholar
  98. Overturf, M.L.; Sybers, H.D.; Druilhet, R.E.; Smith, S.A. and Kirkendall, N.M.: Capoten-induced juxtaglomerular hyperplasia in rabbits. Research Communications in Chemical Pathology and Pharmacology 36: 169–172 (1982).PubMedGoogle Scholar
  99. Peart, W.S.: Renin-angiotensin system. New England Journal of Medicine 292: 302–306 (1975).PubMedCrossRefGoogle Scholar
  100. Pierides, A.M.; Rommel, A.J.; Heald, A.; Kurtz, S.B. and Frohnert, P.P.: Captopril elimination during hemodialysis and in chronic renal failure. Transactions of the American Society of Artificial Internal Organs 9: 59A (1980).Google Scholar
  101. Pierpont, G. and Cohn, J.N.: Comparison of the renal effects of vasodilators used to treat congestive heart failure. Cardiovascular Reviews and Reports 2: 1199–1209 (1981).Google Scholar
  102. Pierpont, G.L.; Francis, G.S. and Cohn, J.N.: Effect of captopril on renal function in patients with congestive heart failure. British Heart Journal 46: 522–527 (1981).PubMedCrossRefGoogle Scholar
  103. Pipkin, F.B.; Symonds, E.M. and Turner, S.R.: The effect of captopril (SQ 14,225) upon mother and fetus in the chronically cannulated ewe and in the pregnant rabbit. Journal of Physiology 323: 415–422(1982).Google Scholar
  104. Pisciotta, A.V.: Immune and toxic mechanisms in drug-induced agranulocytosis. Seminars in Hematology 10: 279–310 (1973).PubMedGoogle Scholar
  105. Prins, E.J.L.; Hoorntje, S.J.; Weening, JJ. and Donker, A.J.M.: Nephrotic syndrome in patients on captopril. Lancet 2: 306–307 (1979).PubMedCrossRefGoogle Scholar
  106. Ribstein, J.; Mimran, A.; Grolleau, R. and Puech, P.: Effect of converting enzyme inhibition (CEI) on renal hemodynamics in congestive heart failure (CHF). Abstracts of the European Congress of Cardiology, Paris, June 22–26 (1980).Google Scholar
  107. Rommel, A.J.; Pierides, A.M. and Heald, A.: Captopril elimination in chronic renal failure. Clinical Pharmacology and Therapeutics 27: 282 (1980).Google Scholar
  108. Rosendorf T,C.; Milne, F.J.; Levy, H.; Ninin, D.T. and Lewin, J.R.: Nephrotic syndrome during captopril therapy. South African Medical Journal 58: 172–173 (1980).Google Scholar
  109. Rouleau, J.L.; Chatterjee, K.; Benge, W.; Parmley, W.W. and Hiramatsu, B.: Alterations in left ventricular function and coronary hemodynamics with captopril, hydralazine and prazosin in chronic ischemic heart failure: A comparative study. Circulation 65: 671–678 (1982).PubMedCrossRefGoogle Scholar
  110. Seedat, Y.K.: Aphthous ulcers of mouth from captopril. Lancet 2: 1297–1298 (1979).PubMedCrossRefGoogle Scholar
  111. Sharpe, D.N.; Coxon, R.J.; Douglas, J.E. and Long, B.: Low-dose captopril in chronic heart failure: acute haemodynamic effects and long-term treatment. Lancet 2: 1154–1157 (1980).PubMedCrossRefGoogle Scholar
  112. Sharpe, D.N. and Coxon, R.: Prazosin and captopril in chronic heart failure: Comparison of acute haemodynamic and hormonal effects. Australian and New Zealand Journal of Medicine (submitted for publication, 1982).Google Scholar
  113. Singhvi, S.M.; Duchin, K.L.; Willard, D.A.; McKinstry, D.N. and Migdalof, B.H.: Renal handling of captopril in normal volunteers: Effects of probenecid. Clinical Pharmacology and Therapeutics 32: 182–189 (1982a).CrossRefGoogle Scholar
  114. Singhvi, S.M.; McKinstry, D.N.; Shaw, J.M.; Willard, D.A. and Migdalof, B.H.: Effect of food on the bioavailability of captopril in healthy subjects. Journal of Clinical Pharmacology 22: 135–140 (1982b).PubMedGoogle Scholar
  115. Snyder, D.W. and Laughlin, W.B.: Lack of a central action of captopril following chronic administration. 55th Scientific Session of the American Heart Association, Dallas, Texas, November 15–18, 1982 (submitted for publication).Google Scholar
  116. Solinger, A.M.: Exfoliative dermatitis from captopril. Cutis 29: 473–474 (1982).PubMedGoogle Scholar
  117. Staessen, J.; Boogaerts, M.; Fagard, R. and Amery, A.: Mechanism of captopril-induced agranulocytosis. Acta Clinica Belgica 36: 87–90(1981).PubMedGoogle Scholar
  118. Swartz, S.L. and Williams, G.H.: Angiotensin-converting enzyme inhibition and prostaglandins. American Journal of Cardiology 49: 1405–1409 (1982).PubMedCrossRefGoogle Scholar
  119. Taher, M.S.; McCain, L.G.; McDonald, K.M. and Schreier, R.W.: Effect of beta-adrenergic blockade on renin response to renal nerve stimulation. Journal of Clinical Investigation 57: 4359 (1976).CrossRefGoogle Scholar
  120. Tarazi, R.C.; Fouad, F.M.; Ceimo, J.K. and Bravo, E.L.: Renin, aldosterone and cardiac decompensation: studies with an oral converting enzyme inhibitor in heart failure. American Journal of Cardiology 44: 1013–1018 (1979).PubMedCrossRefGoogle Scholar
  121. Thibonnier, M.; Soto, M.E.; Menard, J.; Aldiger, J.C.; Corvol, P. and Milliez, P.: Reduction of plasma and urinary vasopressin during treatment of severe hypertension by captopril. European Journal of Clinical Investigation 11: 449–453 (1981).PubMedCrossRefGoogle Scholar
  122. Tobia, A.J. and Giardino, E.C.: Renal vasodilator responses to captopril in dogs pretreated with indomethacin (41157). Proceedings of the Society for Experimental Biology and Medicine 167: 242–247 (1981).PubMedGoogle Scholar
  123. Turini, G.A.; Brunner, H.R.; Ferguson, R.R.; Riviera, J.L. and Gavras, H.: Congestive heart failure in normotensive man. Haemodynamics, renin and angiotensin-II blockade. British Heart Journal 40: 1134–1142 (1978).PubMedCrossRefGoogle Scholar
  124. Turini, G.A.; Brunner, H.R.; Gribic, M.; Waeber, B. and Gavras, H.: Improvement of chronic congestive heart-failure by oral captopril. Lancet 1: 1213–1215 (1979).PubMedCrossRefGoogle Scholar
  125. Van Brummelen, P.; Willemze, R.M.N.; Tan, W.D. and Thompson, J.: Captopril-associated agranulocytosis. Lancet 1: 150 (1980).PubMedCrossRefGoogle Scholar
  126. Vandenburg, M.; Parfrey, P.; Wright, P. and Lazda, E.: Hepatitis associated with captopril treatment. British Journal of Clinical Pharmacology 11: 105–106 (1980).CrossRefGoogle Scholar
  127. Vidt, D.G.; Bravo, E.L. and Fouad, F.M.: Captopril. New England Journal of Medicine 306: 214–219 (1982).PubMedCrossRefGoogle Scholar
  128. Vio, C.P.; Guivernau, M.; Terragno, A. and Terragno, N.A.: Effect of captopril on the biosynthesis of prostaglandins in vitro. Federation Proceedings 40 (Part I): 702 (1981).Google Scholar
  129. Warren, S.E. and O’Connor, D.T.: Hyperkalemia resulting from captopril administration. Journal of the American Medical Association 244: 2551–2552 (1980).PubMedCrossRefGoogle Scholar
  130. Watson, M.A.; Radford, J.N.J.; McGrath, B.P.; Swinton, G.W. and Agar, J.W.M.: Captopril induced agranulocytosis in systemic sclerosis. Australian and New Zealand Journal of Medicine 11: 79–81 (1981).PubMedCrossRefGoogle Scholar
  131. Wenting, G.J.; DeBruyn, J.H.B.; Man in’t Veld, A.J.; Woittiez, A.J.J.; Derkx, F.H.M. and Schalekamp, M.A.D.H.: Hemodynamic effects of captopril in essential hypertension, renovascular hypertension and cardiac failure: Correlations with short and long-term effects on plasma renin. American Journal of Cardiology 49: 1453–1459 (1982).PubMedCrossRefGoogle Scholar
  132. Wilkin, J.K.; Hammond, JJ. and Kirkendall, W.M.: The captopril-induced eruption. Archives of Dermatology 116: 902–905 (1980).PubMedCrossRefGoogle Scholar
  133. Wilkin, J.K. and Kirkendall, W.M.: Pityriasis rosea-like rash from captopril. Archives of Dermatology 118: 186–187 (1982).PubMedCrossRefGoogle Scholar
  134. Williams, G.M. and Sugerman, A.A.: The effect of a meal at various times relative to drug administration, on the bioavailability of captopril. Journal of Clinical Pharmacology 22: 18A (1982).Google Scholar
  135. Witzgall, H.; Hirsch, F.; Scherer, B. and Weber, P.C.: Acute haemodynamic and hormonal effects of captopril are diminished by indomethacin. Clinical Science 62: 611–615 (1982).PubMedGoogle Scholar
  136. Wong, K.K. and Dreyfuss, J.: The in vitro metabolism of 35S-captopril (SQ 14,225) an antihypertensive agent. Pharmacologist 20: 213(1978).Google Scholar
  137. Wong, K.K.; Lan, S.-J. and Migdalof, B.H.: In vitro biotransformations of [I4C] captopril in the blood of rats, dogs and humans. Biochemical Pharmacology 30: 2643–2650 (1981).PubMedCrossRefGoogle Scholar
  138. Zaki, F.G.; Keim, G.R.; Takii, Y. and Inagami, T.: Hyperplasia of juxtaglomerular cells and renin localization in kidneys of normotensive animals given captopril. Electron microscopic and immunohistochemical studies. Annals of Clinical and Laboratory Science 12: 200–215 (1982).PubMedGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd (Inc. NSW) 1983

Authors and Affiliations

  • J. A. Romankiewicz
    • 1
  • R. N. Brogden
    • 1
  • R. C. Heel
    • 1
  • T. M. Speight
    • 1
  • G. S. Avery
    • 1
  1. 1.American Drug Information ServicesAuckland and New YorkUSA

Personalised recommendations